Last reviewed · How we verify
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis (OUTCOMS)
MS is a heterogeneous disease either in its response to treatment or clinical manifestation. Indeed, the natural history of MS is varying from a benign condition to a devastating and rapidly incapacitating disease. Clinical heterogeneity could also be cellular and / or molecular. The aim is to identify from OMIC analyses, at the early stage of the disease, differentially expressed molecules and / or cell subpopulations derived from CD8 + T lymphocytes and / or CD4 + T lymphocytes and / or B lymphocytes and monocytes from patients with aggressive versus non-aggressive, compared to a cohort of healthy controls
Details
| Lead sponsor | Nantes University Hospital |
|---|---|
| Phase | NA |
| Status | RECRUITING |
| Enrolment | 130 |
| Start date | Mon Jan 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Jul 24 2029 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Multiple Sclerosis
Interventions
- Biological sample collection
Countries
France